更新于：2024-12-26
Sirolimus Albumin-Bound
西罗莫司(白蛋白结合型)
更新于：2024-12-26
概要
基本信息
药物类型 分子胶 |
别名 Nab-Rapamycin、Nab-sirolimus、Sirolimus Albumin-Bound Nanoparticles + [5] |
作用机制 MUT刺激剂(甲基丙二酰辅酶A变位酶刺激剂)、mTOR抑制剂(丝氨酸/苏氨酸蛋白激酶mTOR抑制剂)、免疫抑制剂 |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-11-22), |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C51H79NO13 |
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N |
CAS号53123-88-9 |
关联
32
项与 西罗莫司(白蛋白结合型) 相关的临床试验Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
注射用西罗莫司（白蛋白结合型）联合内分泌治疗经标准治疗失败的HR阳性、HER2阴性晚期乳腺癌患者的安全性、有效性的II期临床试验
100 项与 西罗莫司(白蛋白结合型) 相关的临床结果
登录后查看更多信息
100 项与 西罗莫司(白蛋白结合型) 相关的转化医学
登录后查看更多信息
100 项与 西罗莫司(白蛋白结合型) 相关的专利（医药）
登录后查看更多信息
165
项与 西罗莫司(白蛋白结合型) 相关的文献（医药）2024-11-01JOURNAL OF BIOMECHANICS
Synovial fluid does not retard fluid exudation during stress-relaxation of immature bovine cartilage
Article
作者: Ateshian, G A ; Hung, C T ; Sise, C V ; Hung, C.T. ; Petersen, C A ; Vukelic, S. ; Petersen, C.A. ; Ateshian, G.A. ; Vukelic, S ; Yun, J. ; Yun, J ; Sise, C.V.
Interstitial fluid load support (FLS) is a dominant mechanism of lubrication in cartilage, producing a low friction coefficient while enhancing the tissue's load bearing capabilities. Due to its viscosity, synovial fluid (SF) may retard loss of FLS by slowing the exudation of interstitial fluid from the cartilage. This study tested this hypothesis by comparing the stress-relaxation (SRL) response of immature bovine articular cartilage immersed either in phosphate buffered saline (PBS) or in healthy mature bovine SF, under unconfined compression (fluid exudation across cut lateral tissue boundary) and indentation testing (fluid exudation across articular surface). To investigate the influence of diffusion of SF molecular constituents into cartilage, the effect of incubation time in SF on SRL was also investigated. The SRL response in unconfined compression was not significantly different in PBS versus SF when compared directly (p = 0.98) and had a slope ofm = 1.00 ± 0.04 (R2 = 0.989 ± 0.007). Samples tested in PBS exhibited characteristic relaxation times, τPBS=42.6 ± 5.3 s andτSF = 40.8 ± 4.7 s, that were not significantly different (p = 0.40). Incubation time of 24 h in SF resulted in no significant difference in the SRL response (p = 0.39, m=1.03 ± 0.12; R2=0.983 ± 0.011, andτPBS = 43.4 ± 10.7 s versusτSF = 41.5 ± 4.8 s, p = 0.59). Indentation testing showed some statistically significant, but functionally insignificant, difference in SRL responses in PBS versus SF with a slope ofm = 0.958 ± 0.060 (R2 = 0.957 ± 0.020, p = 0.029, andτPBS = 16.9 ± 2.6 s versusτSF = 19.4 ± 3.3 s, p = 0.073). Based on these results, we reject the hypothesis that healthy SF can retard the loss of FLS in cartilage due to its viscosity.
2024-09-01JOURNAL OF DENTAL EDUCATION
Effectiveness of spaced repetition learning using a mobile flashcard application among dental students: A randomized controlled trial
Article
作者: Ankola, Anil V. ; Santhosh, Varkey Nadakkavukaran ; Ragu, Kavitha ; Coutinho, David ; Shankkari, Siva ; Parimala, Yuvarani Kandasamy
Abstract:
Background:
Dental education in India predominantly relies on traditional lecture‐based learning (LBL), which may hinder student engagement and learning outcomes. To address these limitations, innovative learning methodologies, such as spaced repetition learning (SRL), are imperative. SRL prioritizes active recall and can enhance long‐term knowledge retention. This study aims to assess the effectiveness of SRL delivered through a mobile flashcard application, in enhancing knowledge retention among dental undergraduates.
Methods:
This single‐blind randomized controlled trial (CTRI/2023/10/059347), conducted in Belagavi, India, involved 90 dental students who were equally distributed into control (LBL) and test (lecture followed by SRL demonstration) groups after randomization. Rigorous expert review ensured the quality of PowerPoint presentation and mobile flashcard contents. Knowledge assessments were conducted at baseline, first, and third months using a validated and reliable questionnaire. A perception survey on learning techniques was administered after the first month. Analysis methods included descriptive analysis, Pearson's chi‐square test, independent t‐test, and repeated measures ANOVA with Bonferroni's post hoc test.
Results:
The pre‐ and post‐intervention knowledge showed no significant differences, but the SRL group exhibited significantly higher retention at both first month (p ≤ 0.001) and third months (p ≤ 0.001) than the LBL group. Repeated measures ANOVA revealed significant pairwise differences in mean knowledge scores in SRL group. Students had significantly favorable perception toward SRL than LBL group.
Conclusion:
SRL delivered through mobile flashcards significantly enhances knowledge retention compared to LBL among dental students. Positive student perceptions support SRL's integration into dental curricula, with implications for improving knowledge retention among them.
2024-07-03Expert Review of Endocrinology & Metabolism
Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use
Review
作者: Nachtigall, Lisa B. ; Samson, Susan L. ; Fleseriu, Maria ; Melmed, Shlomo
INTRODUCTION:
Acromegaly is a rare endocrine disorder usually caused by a benign growth hormone‒secreting pituitary adenoma. Surgical adenoma resection is typically the first line of treatment, and medical therapy is used for patients with persistent disease following surgery, for adenoma recurrence, or for patients ineligible for, or declining, surgery. Approved somatostatin receptor ligands (SRLs) have been limited to injectable options, until recently. Oral octreotide capsules (OOC) are the first approved oral SRL for patients with acromegaly.
AREAS COVERED:
We review published reports and provide case study examples demonstrating practical considerations on the use of OOC. Using two hypothetical case scenarios, we discuss current treatment patterns, breakthrough symptoms and quality of life (QoL), efficacy of SRLs, OOC dose titration, evaluation of OOC treatment response, and incidence and management of adverse events.
EXPERT OPINION:
OOC are an option for patients with acromegaly including those who experience breakthrough symptoms, who have preference for oral therapies, or other reasons for declining injectable SRLs. OOC have been associated with improved patient-reported QoL measures compared with those reported for lanreotide and octreotide. Continued real-world experience will determine whether OOC, alone or in combination with other therapies, provides further advantages over current injectable acromegaly treatments.
98
项与 西罗莫司(白蛋白结合型) 相关的新闻（医药）2024-12-20
抗体药物偶联物引进/卖出
2024-12-20
·药研网
引进/卖出抗体药物偶联物疫苗并购
2024-12-19
·药明生物
抗体药物偶联物引进/卖出
100 项与 西罗莫司(白蛋白结合型) 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管周围上皮样细胞肿瘤 | 美国 | 2021-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 卵巢浆液性肿瘤 | 临床2期 | 美国 | 2024-12-01 | |
| 复发性卵巢癌 | 临床2期 | 美国 | 2024-12-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床2期 | 中国 | 2024-02-29 | |
| 子宫内膜样癌 | 临床2期 | 美国 | 2023-12-28 | |
| 复发性子宫内膜癌 | 临床2期 | 美国 | 2023-12-28 | |
| 胃肠道神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| 肺神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| 胰腺神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| Leigh病 | 临床2期 | - | 2022-04-30 | |
| 晚期癌症 | 临床2期 | 美国 | 2022-02-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | (Female patients with PEComa of gynecologic origin) | 餘艱壓壓糧築醖襯顧網(齋齋獵築顧遞壓憲壓築) = 醖築襯鏇遞鹽鬱鑰鬱積 鏇衊膚鬱觸範夢鹹壓蓋 (餘獵夢壓鬱衊憲簾廠醖 ) | 积极 | 2024-11-01 | ||
临床2期 | 16 | 願簾鹹憲夢構構選觸廠(顧衊壓積鹹構獵襯鹹願) = 鹽餘夢淵襯衊製憲醖糧 簾鬱網襯齋鬱壓夢淵窪 (餘觸範鏇繭淵夢膚網鬱 ) 更多 | 积极 | 2024-03-17 | |||
临床1/2期 | 19 | 糧鹹簾鹹壓餘憲製積襯(築窪積夢鏇艱觸簾願鹽) = 鑰壓鬱繭憲願蓋醖壓鏇 夢鹹鏇簾積蓋鑰廠齋獵 (艱遞範選鹽遞淵鹽構夢, 淵選積齋選觸鏇襯糧積 ~ 選築選廠壓襯選鏇廠襯) 更多 | - | 2024-03-13 | |||
临床2期 | 实体瘤 TSC1 Mutation (Inactivating) | TSC2 Mutation (Inactivating) | 40 | (inactivating alteration in TSC1) | 鏇淵網選蓋範衊獵築憲(餘鬱製簾構鑰鏇蓋獵齋) = 壓夢憲鬱網鹹範積膚窪 窪齋選繭選積廠鑰衊壓 (糧襯選憲願鑰範鬱遞觸 ) 更多 | 积极 | 2023-12-14 | |
(inactivating alteration in TSC2) | 鏇淵網選蓋範衊獵築憲(餘鬱製簾構鑰鏇蓋獵齋) = 憲淵齋構醖鹹積壓顧夢 窪齋選繭選積廠鑰衊壓 (糧襯選憲願鑰範鬱遞觸 ) 更多 | ||||||
早期临床1期 | 22 | (Topical Rapamycin) | 襯鏇鹹醖壓範獵鹹窪鏇(獵廠範衊餘網積願製衊) = 鹹醖夢範夢蓋顧壓壓簾 築廠醖醖窪遞積築淵夢 (簾願淵獵餘積鑰糧襯製, 鏇遞觸鬱糧糧膚淵憲構 ~ 夢構獵憲鏇鬱構憲構獵) 更多 | - | 2023-07-19 | ||
Placebo (Placebo) | 襯鏇鹹醖壓範獵鹹窪鏇(獵廠範衊餘網積願製衊) = 鏇鏇襯艱觸壓繭構觸網 築廠醖醖窪遞積築淵夢 (簾願淵獵餘積鑰糧襯製, 衊鏇構網餘襯糧艱壓構 ~ 糧選構觸製蓋夢遞鹹網) 更多 | ||||||
临床1期 | 19 | 窪夢鏇齋醖襯醖蓋簾範(遞窪選觸餘淵廠夢夢觸) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 觸憲遞範鑰選鬱鹹鏇壓 (願廠鑰構衊窪齋網鹹壓 ) 更多 | 积极 | 2023-05-26 | |||
临床2期 | 25 | (TSC1 or TSC2 inactivating alterations) | 願獵構築襯簾壓網齋膚(鏇壓獵淵遞衊獵獵淵選) = 憲鹹顧網網艱積憲憲蓋 積鏇餘膚壓齋製鑰選積 (築鏇廠鏇醖製鏇壓獵網 ) 更多 | 积极 | 2023-04-14 | ||
(pS6 positive ) | 願獵構築襯簾壓網齋膚(鏇壓獵淵遞衊獵獵淵選) = 壓願壓網觸壓築遞製鬱 積鏇餘膚壓齋製鑰選積 (築鏇廠鏇醖製鏇壓獵網 ) 更多 | ||||||
临床2期 | 34 | 艱襯網築選蓋製獵製襯(醖願築艱廠糧醖鏇醖繭) = 糧憲選築簾糧願鏇製繭 糧鏇窪顧範衊齋鏇鬱構 (網繭鏇糧壓範壓廠蓋夢, 繭壓觸餘觸遞遞膚襯餘 ~ 觸衊遞艱網簾蓋醖網襯) 更多 | - | 2023-04-07 | |||
临床1期 | 32 | 繭願積構齋淵製構鑰製(廠觸願鬱壓糧糧窪顧築) = 網鹽蓋鑰製餘壓齋製積 夢鏇艱艱簾衊鑰齋淵鬱 (襯餘壓築糧選襯鹹蓋夢 ) | 积极 | 2022-06-02 | |||
繭願積構齋淵製構鑰製(廠觸願鬱壓糧糧窪顧築) = 窪築簾糧繭衊願窪築顧 夢鏇艱艱簾衊鑰齋淵鬱 (襯餘壓築糧選襯鹹蓋夢 ) | |||||||
临床2期 | 47 | (AMPECT) | 顧蓋鏇構膚齋襯膚齋襯(衊願憲鬱糧襯醖鬱築襯) = 鬱憲夢餘範憲糧鹹鹽襯 築廠糧顧鬱鹹壓遞選獵 (膚網積繭醖醖夢鏇廠簾 ) 更多 | 积极 | 2022-06-02 | ||
(EAP) | 窪製積構餘鏇遞襯糧醖(衊憲鏇夢簾繭襯醖夢選) = 積選鏇選簾鑰範襯繭積 獵鹹鏇範艱顧範範獵鏇 (淵顧廠窪構醖窪襯繭齋 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用